ReviewWorld journal of gastroenterology2022
Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations?
Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Changes in Fecal Short-Chain Fatty Acids in IBS Patients and Effects of Different Interventions: A Systematic Review and Meta-Analysis.Nutrients · 2024Pooled it
- The Cost of the Cure: Antibiotic Exposure as a Risk Factor for Irritable Bowel Syndrome.Antibiotics (Basel, Switzerland) · 2026Review
- Circadian gatekeepers of the gut-brain-immune axis: implications for neuroinflammation and neurodegeneration.Journal of neuroinflammation · 2026Review
- FMT from IBS-D Rats Impairs Intestinal Barrier Function and is Associated with Increased Intestinal Benzoic Acid andJournal of microbiology and biotechnology · 2026Article
- The role of gut microbiota-mitochondria crosstalk in neurodegeneration: Underlying mechanisms and potential therapies.Neural regeneration research · 2026Article
- Article
- Investigating the causal roles of cholesterol and triglyceride subfractions across lipoproteins in irritable bowel syndrome: a Mendelian randomization study.Metabolism open · 2026Article
- Effect of combined continuity care guided by Orem's self-care model and low FODMAP diet on gut microbiota composition and symptoms in patients with irritable bowel syndrome.BMC gastroenterology · 2026Article
- Tirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives.Frontiers in microbiology · 2026Review
- Adjunctive use ofTranslational gastroenterology and hepatology · 2026Article
- Low-Grade Inflammation: Pathophysiological Mechanisms and Drug Targets in Irritable Bowel Syndrome with Diarrhea.Journal of inflammation research · 2026Review
- Bidirectional Communication of the Gut-Brain Axis in Pain Regulation: From Microbial Metabolites to Neuroinflammation.Journal of inflammation research · 2026Review
- Comparison of Gut Microbiome Profile of Chickens Infected with ThreeMicroorganisms · 2025Article
- Chronic prostatitis and male infertility: association mechanism and research progress.World journal of urology · 2025Review
- Article
- Review
- Leaky Gut Syndrome: An Interplay Between Nutrients and Dysbiosis.Current nutrition reports · 2025Review
- Chronic Endometritis and Antimicrobial Resistance: Towards a Multidrug-Resistant Endometritis? An Expert Opinion.Microorganisms · 2025Review
- Impact of Microbiota on Irritable Bowel Syndrome Pathogenesis and Management: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- A preliminary study of the association betweenFrontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder in which recurrent abdominal pain is associated with defecation or a change in bowel habits (constipation, diarrhea, or both), and it is often accompanied by symptoms of abdominal bloating and distension. IBS is an important health care issue because it negatively affects the quality of life of patients and places a considerable financial burden on health care systems. Despite extensive research, the etiology and underlying pathophysiology of IBS remain incompletely understood. Proposed mechanisms involved in its pathogenesis include increased intestinal permeability, changes in the immune system, visceral hypersensitivity, impaired gut motility, and emotional disorders. Recently, accumulating evidence has highlighted the important role of the gut microbiota in the development of IBS. Microbial dysbiosis within the gut is thought to contribute to all aspects of its multifactorial pathogenesis. The last few decades have also seen an increasing interest in the impact of antibiotics on the gut microbiota. Moreover, antibiotics have been suggested to play a role in the development of IBS. Extensive research has established that antibacterial therapy induces remarkable shifts in the bacterial community composition that are quite similar to those observed in IBS. This suggestion is further supported by data from cohort and case-control studies, indicating that antibiotic treatment is associated with an increased risk of IBS. This paper summarizes the main findings on this issue and contributes to a deeper understanding of the link between antibiotic use and the development of IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.